Phosphodiesterase 5 inhibitors: current status and potential applications
暂无分享,去创建一个
[1] T. Costigan,et al. P-302: Blood pressure and cardiovascular effects of tadalafil, a new PDE5 inhibitor , 2002 .
[2] T. Costigan,et al. P-313: Efficacy and safety of tadalafil in men with erectile dysfunction with and without hypertension , 2002 .
[3] T. Lampe,et al. Imidazo[5,1-f][1,2,4]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors , 2002 .
[4] H. Porst. IC351 (tadalafil, Cialis): update on clinical experience , 2002, International Journal of Impotence Research.
[5] Y. Nomoto,et al. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5. , 2001, European journal of pharmacology.
[6] C. Sobey. Cerebrovascular Dysfunction After Subarachnoid Haemorrhage: Novel Mechanisms And Directions For Therapy , 2001, Clinical and experimental pharmacology & physiology.
[7] D. Ryu,et al. Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5'-sulfonamide moiety of a phenyl ring. , 2001, Bioorganic & medicinal chemistry.
[8] T. Sekizawa,et al. FR226807: a potent and selective phosphodiesterase type 5 inhibitor. , 2001, European journal of pharmacology.
[9] J. Macor,et al. The discovery of novel, potent and selective PDE5 inhibitors. , 2001, Bioorganic & medicinal chemistry letters.
[10] G. Sybrecht,et al. Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension , 2001, Circulation.
[11] I. Goldstein,et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial , 2001, International Journal of Impotence Research.
[12] J. Ryu,et al. Synthesis and phosphodiesterase 5 inhibitory activity of new 5-phenyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one derivatives containing an N-acylamido group phenyl ring. , 2001, Bioorganic & medicinal chemistry.
[13] H. Inoue,et al. T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats. , 2001, European journal of pharmacology.
[14] J. Kotera,et al. Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives. , 2001, Journal of medicinal chemistry.
[15] S. Lee,et al. Synthesis and phosphodiesterase 5 inhibitory activity of novel phenyl ring modified sildenafil analogues. , 2001, Bioorganic & medicinal chemistry.
[16] L. Lupo,et al. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double‐blind, cross‐over, placebo‐controlled study , 2001, BJOG : an international journal of obstetrics and gynaecology.
[17] W. Klaus,et al. Modulation of Human Platelet Aggregation by the Phosphodiesterase Type 5 Inhibitor Sildenafil , 2001, Journal of cardiovascular pharmacology.
[18] S. Chong,et al. Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction. , 2001, Journal of medicinal chemistry.
[19] M. Bortolotti,et al. Sildenafil inhibits gastroduodenal motility , 2001, Alimentary pharmacology & therapeutics.
[20] R. Engelmann,et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study , 2001, World Journal of Urology.
[21] H. Inoue,et al. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. , 2001, European journal of pharmacology.
[22] K. Fujishige,et al. Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7- (2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). , 2000, Biochemical pharmacology.
[23] W. Kim,et al. Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159 , 2000, Archives of pharmacal research.
[24] I. Goldstein,et al. Sildenafil augments pelvic nerve‐mediated female genital sexual arousal in the anesthetized rabbit , 2000, International Journal of Impotence Research.
[25] S. Kurowski,et al. Sildenafil relaxes rabbit clitoral corpus cavernosum. , 2000, Life sciences.
[26] J. Corbin,et al. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. , 2000, European journal of biochemistry.
[27] J. Beavo,et al. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. , 2000, Current opinion in cell biology.
[28] J. Beavo,et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Macor,et al. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. , 2000, Journal of medicinal chemistry.
[30] T. Lue,et al. Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. , 2000, Biochemical and biophysical research communications.
[31] M. Bortolotti,et al. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. , 2000, Gastroenterology.
[32] K. Murray,et al. A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein , 1999, FEBS letters.
[33] J. Corbin,et al. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. , 1999, Molecular pharmacology.
[34] J. Corbin,et al. Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* , 1999, The Journal of Biological Chemistry.
[35] C. Conti,et al. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. , 1999, The American journal of cardiology.
[36] S. Kaplan,et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. , 1999, Urology.
[37] B P Gardner,et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury , 1998, Neurology.
[38] M. Fava,et al. An Open Trial of Oral Sildenafilin Antidepressant-Induced Sexual Dysfunction , 1998, Psychotherapy and Psychosomatics.
[39] D. Price,et al. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[40] K. Ferguson,et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. , 1998, Gene.
[41] K. Fujishige,et al. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. , 1998, European journal of biochemistry.
[42] J. Corbin,et al. Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity. , 1998, Biochemistry.
[43] Andrew Simon Bell,et al. Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .
[44] W. K. Sonnenburg,et al. The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. , 1993, The Journal of biological chemistry.
[45] T. Lincoln,et al. Characterization of a novel cGMP binding protein from rat lung. , 1980, The Journal of biological chemistry.
[46] T. Wilt,et al. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. , 2002, The Journal of urology.
[47] R. Kloner,et al. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. , 2001, American journal of hypertension.
[48] D. Rotella. Phosphodiesterase type 5 inhibitors: Discovery and therapeutic utility , 2001 .
[49] P. Cartwright,et al. Granulocytic sarcoma presenting as testicular and paratesticular masses in infancy. , 2001, The Journal of urology.